Interactive Features

Quiz

Front-Line Treatment Options for Ovarian Cancer

12/20/2023

Oncology

Quiz

New and Emerging Targeted Therapies for Relapsing Ovarian Cancer

11/29/2023

Oncology

Quiz

Maintenance Olaparib Rechallenge for Ovarian Cancer

10/31/2023

Oncology

Quiz

Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer

05/16/2023

How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?

How is Sleeping Beauty...

05/16/2023

Oncology

Quiz

Quiz: FDA Approves Mirvetuximab Soravtansine

12/15/2022

What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?

What treatment must patients...

12/15/2022

Oncology

Quiz

Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice

12/02/2022

What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?

What is the most prevalent...

12/02/2022

Oncology

Quiz

Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer

11/03/2022

A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?

A phase 3 open-label study found...

11/03/2022

Oncology

Quiz

Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer

03/27/2022

True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.

True or false: Researchers at...

03/27/2022

Oncology

Test Your Knowledge

Quiz: A Common Thread in Rising Endometrial Cases in US Women

05/29/2021

Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?

Quiz: Among young adult women in...

05/29/2021

Oncology

Test Your Knowledge

Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?

05/28/2021

True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.

True or False: Study findings...

05/28/2021

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology